Literature DB >> 18837917

Circulating nucleic acids in plasma and serum. Recent developments.

Peter B Gahan1, R Swaminathan.   

Abstract

DNA and RNA fractions have been isolated from the whole blood, serum, plasma, the surface of blood cells, and urine of both healthy individuals and patients. The ability to isolate, quantify, and analyze these molecules has led to the identification of specific nucleic acid fragments related to particular disorders such as diabetes, cancer, myocardial infarction, and stroke, thereby permitting their early diagnosis. Currently, a number of methods for isolating the nucleic acids are employed and although a start has been made to compare the efficiencies of these methods, there is still a way to go before there are precise protocols for nucleic acid extraction. The older chemical methods of extraction still outperform some of the available kits. Some progress is being made to determine the origin of the circulating nucleic acids, although there are still many questions to be answered, including whether the source is through the spontaneous release of newly synthesized nucleic acid or whether it just derived from necrotic and apoptotic cells. In addition, it can be demonstrated that the nucleic acids can enter cells and exhibit a biological activity in the recipient cells. Hence, the question remains: Are the circulating nucleic acids freely entering tissues and cells from the blood and inducing changes in those tissues and cells? Further work is needed to elucidate these areas, and the various protocols must be standardized if the new methodology is to be widely and accurately applied in the diagnosis of disease and the monitoring of therapy. This chapter summarizes the work reported in this volume.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837917     DOI: 10.1196/annals.1448.050

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  41 in total

1.  LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.

Authors:  Ana Aparicio; Brittany North; Lindsey Barske; Xuemei Wang; Valentina Bollati; Daniel Weisenberger; Christine Yoo; Nizar Tannir; Erin Horne; Susan Groshen; Peter Jones; Allen Yang; Jean-Pierre Issa
Journal:  Epigenetics       Date:  2009-04-06       Impact factor: 4.528

2.  Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology.

Authors:  Anastasia Katsiampoura; Scott Kopetz
Journal:  Gastrointest Cancer Res       Date:  2014-09

3.  Noninvasive preimplantation genetic testing for aneuploidy in spent medium may be more reliable than trophectoderm biopsy.

Authors:  Lei Huang; Berhan Bogale; Yaqiong Tang; Sijia Lu; Xiaoliang Sunney Xie; Catherine Racowsky
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

Review 4.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

5.  Placental mosaicism for Trisomy 13: a challenge in providing the cell-free fetal DNA testing.

Authors:  Xiang-Yin Liu; Hong-Guo Zhang; Rui-Xue Wang; Shuang Chen; Xiao-Wei Yu; Rui-Zhi Liu
Journal:  J Assist Reprod Genet       Date:  2014-02-05       Impact factor: 3.412

Review 6.  A historical and evolutionary perspective on the biological significance of circulating DNA and extracellular vesicles.

Authors:  Janine Aucamp; Abel J Bronkhorst; Christoffel P S Badenhorst; Piet J Pretorius
Journal:  Cell Mol Life Sci       Date:  2016-09-20       Impact factor: 9.261

Review 7.  Liquid Biopsies in Oncology and the Current Regulatory Landscape.

Authors:  Lindsay N Strotman; Lori M Millner; Roland Valdes; Mark W Linder
Journal:  Mol Diagn Ther       Date:  2016-10       Impact factor: 4.074

Review 8.  Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker.

Authors:  Mersedeh Rohanizadegan
Journal:  Cancer Genet       Date:  2018-02-24

Review 9.  Point-of-care technologies for molecular diagnostics using a drop of blood.

Authors:  Yujun Song; Yu-Yen Huang; Xuewu Liu; Xiaojing Zhang; Mauro Ferrari; Lidong Qin
Journal:  Trends Biotechnol       Date:  2014-02-11       Impact factor: 19.536

10.  Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer.

Authors:  Bo Gong; Jianxiang Xue; Jing Yu; Haichuan Li; Heyu Hu; Hsuehheng Yen; Jinyin Hu; Qianggang Dong; Fuhua Chen
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.